You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Palbociclib

Showing 326 - 348 of 348
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumors, Lymphoma, Non-Hodgkin Trial in Detroit, New York, Philadelphia (PD-0332991)

Completed
Has Results
  • Neoplasms
  • Lymphoma, Non-Hodgkin
  • Detroit, Michigan
  • +3 more
Dec 3, 2015

Healthy Trial in Miami, South Miami (Palbociclib Alone, Palbociclib + Rabeprazole)

Completed
  • Healthy
  • Palbociclib Alone
  • Palbociclib + Rabeprazole
  • Miami, Florida
  • +2 more
May 27, 2015

Healthy Trial in South Miami (Midazolam, PD-0332991)

Completed
  • Healthy
  • South Miami, Florida
    Pfizer Investigational Site
Oct 6, 2015

Lymphoma, Mantle-Cell Trial in Boston, New York, Philadelphia (PD-0332991)

Completed
Has Results
  • Lymphoma, Mantle-Cell
  • Boston, Massachusetts
  • +5 more
Oct 6, 2015

Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma Trial in San Francisco (PD 0332991 (pre-surgery), PD 0332991, Resection as

Terminated
Has Results
  • Glioblastoma
  • +2 more
  • PD 0332991 (pre-surgery)
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 15, 2015

Healthy Trial in New Haven (Palbociclib alone, Palbociclib plus Modafinil, Palbociclib plus pioglitazone)

Completed
  • Healthy
  • Palbociclib alone
  • +2 more
  • New Haven, Connecticut
    New Haven Clinical Research Unit
Feb 18, 2015

Untreated Operable Early Breast Cancer Trial in Villejuif (PD0332991)

Completed
  • Untreated Operable Early Breast Cancer
  • Villejuif, Val de Marne, France
    Gustave Roussy
Jun 8, 2016

Melanoma BRAF V600E/K Mutated, CDNKN2A Loss Defined Trial in Paris (PD- 0332991)

Unknown status
  • Melanoma BRAF V600E/K Mutated
  • CDNKN2A Loss Defined
  • PD- 0332991
  • Paris, France
    Saint-Louis Hospital
Apr 15, 2016

Multiple Myeloma Trial in Czech Republic, Germany, United States (Bortezomib, Dexamethasone, PD 0332991)

Completed
Has Results
  • Multiple Myeloma
  • Chicago, Illinois
  • +18 more
Mar 4, 2015

Healthy Trial in New Haven (Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg)

Completed
  • Healthy
  • Palbociclib 75mg
  • +3 more
  • New Haven, Connecticut
    Pfizer Investigational Site
Jun 23, 2014

Healthy Trial in New Haven (Palbociclib Alone, Palbociclib plus itraconazole)

Completed
  • Healthy
  • Palbociclib Alone
  • Palbociclib plus itraconazole
  • New Haven, Connecticut
    Pfizer Investigational Site
Jun 27, 2014

Healthy Trial in New Haven (Palbociclib Formulation Reference, Palbociclib Formulation Test)

Completed
  • Healthy
  • Palbociclib Formulation Reference
  • Palbociclib Formulation Test
  • New Haven, Connecticut
    Pfizer Investigational Site
Jun 2, 2014

Healthy Trial in New Haven (palbociclib commercial free base, famotidine, rabeprazole)

Completed
  • Healthy
  • palbociclib commercial free base
  • +3 more
  • New Haven, Connecticut
    Pfizer Investigational Site
Jun 17, 2014

Healthy Trial in New Haven (palbociclib isethionate (phase 1 and 2 studies), palbociclib commercial free base capsule)

Completed
  • Healthy
  • palbociclib isethionate (phase 1 and 2 studies)
  • palbociclib commercial free base capsule
  • New Haven, Connecticut
    Pfizer Investigational Site
Mar 14, 2014

Healthy Trial in New Haven (Palbociclib, Rifampin)

Completed
  • Healthy
  • New Haven, Connecticut
    Pfizer Investigational Site
Jan 16, 2014

Healthy Trial in Overland Park (palbociclib capsule: phase 1 and 2 studies, Palbociclib capsule: phase 3 studies, Palbociclib

Completed
  • Healthy
  • palbociclib capsule: phase 1 and 2 studies
  • +2 more
  • Overland Park, Kansas
    Pfizer Investigational Site
Jan 17, 2014

Healthy Trial in New Haven (Palbociclib administered Fasted, Palbociclib administered Fed high calorie, Palbociclib administered

Completed
  • Healthy
  • Palbociclib administered Fasted
  • +3 more
  • New Haven, Connecticut
    Pfizer Investigational Site
Dec 16, 2013

Healthy Trial in NOttingham (Oral Drug Formulation of PD-0332991, Intravenous Formulation of PD-0332991)

Completed
  • Healthy
  • Oral Drug Formulation of PD-0332991
  • Intravenous Formulation of PD-0332991
  • NOttingham, Nottinghamshire, United Kingdom
    Pfizer Investigational Site
Dec 16, 2013

Healthy Trial in Tacoma ([14C]-PD-0332991)

Completed
  • Healthy
  • [14C]-PD-0332991
  • Tacoma, Washington
    Pfizer Investigational Site
Dec 16, 2013

Healthy Trial in New Haven (Palbociclib Formulation Reference, Palbociclib Formulation Test)

Completed
  • Healthy
  • Palbociclib Formulation Reference
  • Palbociclib Formulation Test
  • New Haven, Connecticut
    Pfizer Investigational Site
Aug 27, 2013

ER Positive, HER2 Negative Breast Cancer Trial in Hong Kong (Letrozole, PD 0332991)

Unknown status
  • ER Positive, HER2 Negative Breast Cancer
  • Letrozole, PD 0332991
  • Hong Kong, China
    Unimed Medical Institute
Dec 29, 2013

Relapsed Acute Leukemia, Refractory Acute Leukemia, High-Risk Myelodysplasia Trial in Baltimore, New York (PD 0332991)

Terminated
Has Results
  • Relapsed Acute Leukemia
  • +2 more
  • PD 0332991
  • Baltimore, Maryland
  • +1 more
Aug 30, 2013

Healthy Trial in New Haven (PD-0332991)

Completed
  • Healthy
  • New Haven, Connecticut
    Pfizer Investigational Site
Nov 8, 2012